Apremilast as a treatment for psoriasis

Bibliography

• Patel RV, Lebwohl M. In the clinic. Psoriasis. Ann Intern Med 2011;155:ITC2-1-ITC2-15
   Web of Science ®Google Scholar
• Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med 2009;361(5):496-509
   PubMed Web of Science ®Google Scholar
• Kurd SK, Gelfand JM. The prevalence of previously diagnosed psoriasis in US adults: results from NHANES 2003 – 2004. J Am Acad Dermatol 2009;60(2):218-24
   PubMed Web of Science ®Google Scholar
• Staidle JP, Dabade TS, Feldman SR. A pharmacoeconomic analysis of severe psoriasis therapy: a review of treatment choices and cost efficiency. Expert Opin Pharmacother 2011;12:2041-54
   PubMed Web of Science ®Google Scholar
• Russo PA, Ilchef R, Cooper AJ. Psychiatric morbidity in psoriasis: a review. Australas J Dermatol 2004;45:155-9
   PubMedGoogle Scholar
• Perrott SB, Murray AH, Lowe J, Mathieson CM. The psychosocial impact of psoriasis: physical severity, quality of life and stigmatization. Phyiol Behav 2000;70:567-71
   PubMed Web of Science ®Google Scholar
• Takahashi H, Iizuka H. Psoriasis and metabolic syndrome. J Dermatol 2011; Epub ahead of print
   Google Scholar
• Li W, Han J, Choi HK, Qureshi AA. Smoking and risk of incident psoriasis among women and men in the United States: a combined analysis. Am J Epidemiol 2012. [Epub ahead of print]
   Google Scholar
• Green L.. An overview and update of psoriasis. Nurs Stand 2011;25:47-55
   PubMedGoogle Scholar
• Menter A, Gottlieb A, Feldman SR, Guidelines of care of the management of psoriasis and psoriatic arthritis: section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol 2008;58(5):826-50
   PubMed Web of Science ®Google Scholar
• Menter A, Korman NJ, Elmets CA, Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions. J Am Acad Dermatol 2011;65(1):137-74
   PubMed Web of Science ®Google Scholar
• Murphy G, Reich K. In touch with psoriasis: topical treatments and current guidelines. J Eur Acad Dermatol Venereol 2011;25(Suppl 4):3-8
   PubMedGoogle Scholar
• Hsu S, Papp KA, Lebwohl MG, Consensus guidelines for the management of plaque psoriasis. Arch Dermatol 2012;146(1):95-102
   Google Scholar
• Sukarovska BG, Lipozencic J, Vrzogic P. Topical corticosteroids and corticosteroid sparing therapy in psoriasis management. Acta Med Croatica 2007;61(4):375-81
   PubMedGoogle Scholar
• Reich K, Bewley A. What is new in topical therapy for psoriasis? J Eur Acad Dermatol Venereol 2011;25(Suppl 4):15-20
   PubMed Web of Science ®Google Scholar
• Del Rosso J, Friedlander SF. Corticosteroids: options in the era of steroid-sparing therapy. J Am Acad Dermatol 2005;53(1, Suppl 1):S50-8
   PubMed Web of Science ®Google Scholar
• Kurian A, Barankin B. Current effective topical therapies in the management of psoriasis. Skin Therapy Lett 2011;16(1):4-7
   PubMedGoogle Scholar
• Duvic M, Nagpal S, Asano AT, Molecular mechanisms of tazarotene action in psoriasis. J Am Acad Dermatol 1997;37(2,Pt3):S18-24
   Google Scholar
• Scheinfled N.. The use of topical tacrolimus and pimecrolimus to treat psoriasis: a review. Dermatol Online J 2004;10(1):3
   Google Scholar
• Reynolds NJ, Al-Daraji WI. Calcineurin inhibitors and sirolimus: mechanisms of action and applications in dermatology. Clin Exp Dermatol 2002;27(7):555-61
   PubMed Web of Science ®Google Scholar
• Kemeny L, Ruzicka T, Braun-Falco O. Dithranol: a review of the mechanism of action in the treatment of psoriasis vulgaris. Skin Pharmacol 1990;3(1):1-20
   PubMedGoogle Scholar
• Horn EJ, Domm S, Katz HI, Topical corticosteroids in psoriasis: strategies for improving safety. J Eur Acad Dermatol Venereol 2010;24(2):119-24
   PubMed Web of Science ®Google Scholar
• Ryan C, Abramson A, Patel M, Menter A. Current investigational drugs in psoriasis. Expert Opin Investig Drugs 2012;21(4):473-87
   PubMed Web of Science ®Google Scholar
• Balkrishnan R, Carroll CL, Camacho FT, Feldman SR. Electronic monitoring of medication adherence in skin disease: results of a pilot study. J Am Acad Dermatol 2003;49(4):651-4
   PubMed Web of Science ®Google Scholar
• McDonald HP, Garg AX, Haynes RB. Interventions to enhance patient adherence to medication prescriptions: scientific review. JAMA 2002;288(22):2868-79; Review. Erratum in: JAMA. 2003;289(24):3242
   PubMed Web of Science ®Google Scholar
• Cork MJ, Britton J, Butler L, Comparison of parent knowledge, therapy utilization and severity of atopic eczema before and after explanation and demonstration of topical therapies by a specialist dermatology nurse. Br J Dermatol 2003;149(3):582-9
   PubMed Web of Science ®Google Scholar
• Krejci-Manwaring J, Tusa MG, Carroll C, Stealth monitoring of adherence to topical medication: adherence is very poor in children with atopic dermatitis. J Am Acad Dermatol 2007;56(2):211-16
   PubMed Web of Science ®Google Scholar
• Richards HL, Fortune DG, O'Sullivan TM, Patients with psoriasis and their compliance with medication. J Am Acad Dermatol 1999;41(4):581-3
   PubMed Web of Science ®Google Scholar
• Rapp SR, Exum ML, Reboussin DM, The Physical, psychological and social impact of psoriasis. J Health Psychol 1997;2:525-37
   PubMedGoogle Scholar
• Menter A, Korman NJ, Elmets CA, Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J Am Acad Dermatol 2009;61(3):451-85
   PubMed Web of Science ®Google Scholar
• Braddock M, Murray C. 10th anniversary inflammation and immune diseases drug discovery and development summit. Expert Opin Investig Drugs 2006;15:721-7
   PubMedGoogle Scholar
• Gottlieb AB, Strober B, Krueger An open-label, single-arm pilot study in patients with severe plaque-type psoriasis treated with an oral anti-inflammatory agent, apremilast. Curr Med Res Opin 2008;24:1529-38
   PubMed Web of Science ®Google Scholar
• Hoffmann M, Kumar G, Schafer P, Disposition, metabolism, and mass balance of [14C] apremilast following oral administration. Xenobiotica 2011;41:1063-75
   PubMed Web of Science ®Google Scholar
• Man HW, Schafer P, Wong LM, Discovery of (S)-N-{2-[1-(3-Ethoxy-4-methoxy-phenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl}acetamide (apremilast), a potent and orally active phosphodiesterase 4 and tumor necrosis factor-alpha inhibitor. J Med Chem 2009;52:1522-4
   PubMed Web of Science ®Google Scholar
• Schafer PH, Parton A, Gandhi AK, Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis. Br J Pharmacol 2010;159:842-55
   PubMed Web of Science ®Google Scholar
• Houslay MD, Schafer P, Zhang KY. Keynote review: phosphodiesterase-4 as a therapeutic target. Drug Discov Today 2005;10(22):1503-19
   PubMed Web of Science ®Google Scholar
• Houslay MD, Adams DR. PDE4 cAMP phosphodiesterases: modular enzymes that orchestrate signaling cross-talk, desensitization and compartmentalization. Biochem J 2003;370(Pt 1):1-18
   PubMed Web of Science ®Google Scholar
• Houslay MD.. Underpinning compartmentalised camp signaling through targeted camp breakdown. Trends Biochem Sci 2010;35(2):91-100
   PubMed Web of Science ®Google Scholar
• Houslay MD, Baillie GS, Maurice DH. cAMP-Specific phosphodiesterase-4 enzymes in the cardiovascular system: a molecular toolbox for generating compartmentalized cAMP signaling. Circ Res 2007;10(7):950-66
   Google Scholar
• Schafer PH, Parton A, Gandhi AK, Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis. Br J Pharmacol 2010;159(4):842-55
   PubMed Web of Science ®Google Scholar
• Gloerich M, Bos JL. Epac: defining a new mechanism for cAMP action. Annu Rev Pharmacol Toxicol 2010;50:355-75
   PubMed Web of Science ®Google Scholar
• Scheibner KA, Boodoo S, Collins S, The adensosine a2a receptor inhibits matrix-induced inflammation in a novel fashion. Am J Respir Cell Mol Biol 2009;40(3):251-9
   PubMedGoogle Scholar
• Xing J, Birukova AA. ANP attenuates inflammatory signaling and Rho pathway of lung endothelial permeability induced by LPS and TNFalpha. Microvasc Res 2010;79(1):56-62
   PubMedGoogle Scholar
• Xu XJ, Reichner JS, Mastrofrancesco B, Prostaglandin E2 suppresses lipopolysaccharide-stimulated IFN-beta production. J Immunol 2008;180(4):2125-31
   PubMedGoogle Scholar
• Baughman RP, Judson MA, Ingledue R, Efficacy and safety of apremilast in chronic cutaneous sarcoidosis. Arch Dermatol 2011; published online 17 October 2011; doi:10.1001/archdermatol.2011.301
   PubMedGoogle Scholar
• Gordan JN, Prothero JD, Thornton CA, CC-10004 but not thalidomide or lenalidomide inhibits lamina propria mononuclear cell TNF-alpha and MMP-3 production in patients with inflammatory bowel disease. J Crohns Colitis 2009;3:175-82
   PubMedGoogle Scholar
• Khobzaoui M, Gutke HJ, Burnet M. CC-10004. Curr Opin Investig Drugs 2005;6:518-25
   PubMedGoogle Scholar
• McCann FE, Palfreeman AC, Andrews M, Apremilast, a novel PDE4 inhibitor, inhibits spontaneous production of tumor necrosis factor-alpha from human rheumatoid synovial cells and ameliorates experimental arthritis. Arthritis Res Ther 2010;12:R107
   PubMed Web of Science ®Google Scholar
• Paramio JM, Casanova ML, Segrelles C, Modulation of cell proliferation by cytokeratins K10 and K16. Mol Cell Biol 1999;19(4):3086-94
   PubMedGoogle Scholar
• Krueger GG, Feldman SR, Camisa C, Two considerations for patients with psoriasis and their clinicians: what defines mild, moderate and severe psoriasis? What constitutes a clinically significant improvement when treating psoriasis? J Am Acad Dermatol 2000;43:281-5
   PubMed Web of Science ®Google Scholar
• Papp K, Zeldis J, Rohane P, Thaci D. A phase 2 study demonstrating the efficacy and safety of the oral therapy CC-10004 in subjects with moderate to severe psoriasis. J Am Acad Dermatol 2008;58(2, Suppl 2):abstract P2614
   Google Scholar
• Tomillero A, Moral MA. Gateways to clinical trials. Methods Find Exp Clin Pharmacol 2008;30:313-31
   PubMedGoogle Scholar
• Papp K, Hu A, Day R. Oral apremilast is active in the treatment of moderate to severe plaque psoriasis: results from a phase 2b, randomized, controlled study (PSOR-005) [abstract 273]. J Invest Dermatol 2011;131:S46
   PubMedGoogle Scholar
• Apremilast. Clinicaltrials.gov: A service of the U.S. National Institutes of Health. Available from: http://clinicaltrials.gov/ct2/results?flds=Xf&flds=a&flds=b&term=apremilast&show_flds=Y [Accessed 23 December 2011]
   Google Scholar
• Pinner NA, Hamilton LA, Hughes A. Roflumilast: a phosphodiesterase-4 inhibitor for the treatment of severe chronic obstructive pulmonary disease. Clin Ther 2012;34(1):56-66
   PubMed Web of Science ®Google Scholar
• Kosari P, Feldman SR. Case report: fluocinonide-induced perioral dermatitis in a patient with psoriasis. Dermatol Online J 2009;15(3):15
   PubMedGoogle Scholar
• Tempark T, Phatarakijnirund V, Chatproedprai S, Exogenous Cushing's syndrome due to topical corticosteroid application: case report and review literature. Endocrine 2010;38(8):328-34
   PubMedGoogle Scholar
• Gottlieb A, Korman NJ, Gordon KB, Guidelines of care for the management of psoriasis and psoriatic arthritis: section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on biologics. J Am Acad Dermatol 2008;58(5):851-64
   PubMed Web of Science ®Google Scholar
• Menter A, Gottlieb A, Feldman SR, Guidelines of care for the management of psoriasis and psoriatic arthritis: section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol 2008;58(5):826-50
   PubMed Web of Science ®Google Scholar
• Montaudie H, Sbidian E, Paul C, Methotrexate in psoriasis: a systematic review of treatment modalities, incidence, risk factors and monitoring of liver toxicity. J Eur Acad Dermatol Venereol 2011;25(Suppl 2):12-18
   PubMed Web of Science ®Google Scholar
• Maza A, Montaudie H, Sbidian E, Oral cyclosporine in psoriasis: a systematic review on treatment modalities, risk of kidney toxicity and evidence for use in non-plaque psoriasis. J Eur Acad Dermatol Venereol 2011;25(Suppl 2):19-27
   PubMed Web of Science ®Google Scholar
• Houslay MD, Schafer P, Zhang KY. Keynote review: phosphodiesterase-4 as a therapeutic target. Drug Discov Today 2005;10(22):1503-19
   PubMed Web of Science ®Google Scholar
• Lipworth BJ. Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease. Lancet 2005;365:167-75
   PubMed Web of Science ®Google Scholar
• Daliresp [package insert]. Forrest Pharmaceuticals; St. Louis, Mo: 2010
   Google Scholar